Photetica

Supportive Technology aimed at eliminating or reducing significant Chemotherapy side effects.

Photetica has developed and patented an innovative science, delivered via a portable medical device, named Lazarus.

The primary target market is Oncology/Therapeutic..

Future planned markets include Diabetes (Diabetic peripheral neuropathy), HIV (Peripheral neuropathy), Migraines, Rheumatoid Arthritis, Psoriatic Arthritis, Fibromyalgia, Shingles, Lyme’s Disease, and overall Quality of Life.

We are about to begin Phase II clinical studies in collaboration with one of the most esteemed clinics in Healthcare.

Oncology market entry anticipated as Q1 2016.

This medical device, designed for the medical and consumer markets, is non-invasive, portable, easy to use, ship and service.

ONCOLOGY/THERAPEUTIC MARKETS:
1) Drug Induced Peripheral Neuropathy
2) Chemotherapy Induced Peripheral Neuropathy (CIPN)
3) Stabilization of Neutrophil (White Blood Cell) Count
4) Migraines/Headaches
5) Quality of Life (QOL)

ADDITIONAL MARKETS
1) Migraines
2) Arthritis (Rheumatoid & Psoriatic)
3) Fibromyalgia
4) Shingles
5) HIV
6) Diabetes
7) Lyme’s Disease
8) Quality of Life

Company’s Keywords:

migraines & pain, improving the immune system, eliminating or reducing significant chemo side effects, improving overall quality of life